TrialActa dermato-venereologica2024

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.

Enzo Errichetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.